GENERAL
Lupin Carves Out 2 Cancer Therapy Programmes Into New US Venture
Global pharmaceutical major Lupin Ltd has announced the strategic spin-out of two of its oncology programmes into Kaveri Therapeutics Inc., a US-based clinical-stage oncology company, in a move aimed at accelerating the global development of targeted cancer therapies. Independent platform for oncology development The spin-out will be executed through Lupin Inc., the company’s wholly owned […]
CW Bureau
·
Jul 21, 2026
GENERAL
Lupin Banks On Biosimilars, Specialty Medicines To Power Next Expansion
Lupin Ltd is stepping up its focus on biosimilars, specialty medicines, complex generics and artificial intelligence (AI) as it builds the next phase of its growth strategy, according to Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta in a joint message to shareholders in the company’s Annual Report 2026. The leadership said years […]
CW Bureau
·
Jul 14, 2026
GENERAL
Lupin Enters TIME-Statista’s World’s Most Sustainable Companies List
Global pharmaceutical major Lupin Ltd. has made its debut on TIME and Statista’s World’s Most Sustainable Companies 2026 list. It is ranked 318th among 750 companies selected from more than 5,000 of the world’s largest and most influential organisations. Only 16 Indian companies Lupin is among 16 Indian companies featured in this year’s global ranking. […]
CW Bureau
·
Jul 6, 2026
GENERAL
Lupin Secures USFDA Approval For Ranibizumab Biosimilar Ranluspec
Global pharmaceutical major Lupin has received approval from the US Food and Drug Administration (FDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis, marking a significant milestone in the company’s expanding biosimilars portfolio. The approval makes Ranluspec the only interchangeable ranibizumab biosimilar in the United States available in both vial and pre-filled syringe (PFS) presentations. […]
CW Bureau
·
Jun 5, 2026
GENERAL
Lupin Gets Clean Inspection Report From US FDA For Ankleshwar Plant
Pharma major Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility in Gujarat following the closure of a product-specific pre-approval inspection conducted between March 2 and March 7, 2026. The receipt of the EIR marks the successful […]
CW Bureau
·
May 28, 2026
